Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Adenosine Signaling in Primary and Metastatic Brain Tumors: Immune Suppression, Tumor Progression, and Therapeutic Opportunities.

Molecular neurobiology·2026
Same author

Targeting purinergic signaling and MTAP-associated metabolism in cancer: A functional immunometabolic convergence framework.

Biochemical pharmacology·2026
Same author

Genetic alterations in SUPT6H are associated with neurodevelopmental disorders.

Biochimica et biophysica acta. Molecular basis of disease·2026
Same author

AES-NINDS Epilepsy Benchmarks Area IV: Comorbidities of Epilepsy - Where Are We and Where Will We Go?

Epilepsy currents·2026
Same author

Commonalities in gene expression and methylation changes across two rat models of acquired epilepsy.

Scientific reports·2026
Same author

The Concise Guide to PHARMACOLOGY 2025/26: Enzymes.

British journal of pharmacology·2025

Related Experiment Video

Updated: Jun 10, 2026

Protocol for MicroRNA Transfer into Adult Bone Marrow-derived Hematopoietic Stem Cells to Enable Cell Engineering Combined with Magnetic Targeting
11:37

Protocol for MicroRNA Transfer into Adult Bone Marrow-derived Hematopoietic Stem Cells to Enable Cell Engineering Combined with Magnetic Targeting

Published on: June 18, 2018

Engineering human mesenchymal stem cells to release adenosine using miRNA technology.

Gaoying Ren1, Detlev Boison

  • 1Department of Medicine, University of Washington, Seattle, WA, USA.

Methods in Molecular Biology (Clifton, N.J.)
|August 6, 2010
PubMed
Summary

Engineered stem cells can release adenosine to protect brain cells. Lentiviral RNAi successfully reduced adenosine kinase (ADK) in human mesenchymal stem cells (hMSCs), enabling neuroprotection in a mouse seizure model.

More Related Videos

Isolating, Sequencing and Analyzing Extracellular MicroRNAs from Human Mesenchymal Stem Cells
10:55

Isolating, Sequencing and Analyzing Extracellular MicroRNAs from Human Mesenchymal Stem Cells

Published on: March 8, 2019

Isolation, Characterization and MicroRNA-based Genetic Modification of Human Dental Follicle Stem Cells
07:56

Isolation, Characterization and MicroRNA-based Genetic Modification of Human Dental Follicle Stem Cells

Published on: November 16, 2018

Related Experiment Videos

Last Updated: Jun 10, 2026

Protocol for MicroRNA Transfer into Adult Bone Marrow-derived Hematopoietic Stem Cells to Enable Cell Engineering Combined with Magnetic Targeting
11:37

Protocol for MicroRNA Transfer into Adult Bone Marrow-derived Hematopoietic Stem Cells to Enable Cell Engineering Combined with Magnetic Targeting

Published on: June 18, 2018

Isolating, Sequencing and Analyzing Extracellular MicroRNAs from Human Mesenchymal Stem Cells
10:55

Isolating, Sequencing and Analyzing Extracellular MicroRNAs from Human Mesenchymal Stem Cells

Published on: March 8, 2019

Isolation, Characterization and MicroRNA-based Genetic Modification of Human Dental Follicle Stem Cells
07:56

Isolation, Characterization and MicroRNA-based Genetic Modification of Human Dental Follicle Stem Cells

Published on: November 16, 2018

Area of Science:

  • Biomedical Engineering
  • Neuroscience
  • Stem Cell Biology

Background:

  • Adenosine plays crucial roles in tissue protection and metabolic regulation.
  • Adenosine kinase (ADK) controls intracellular and extracellular adenosine levels.
  • Engineering adenosine-releasing cells holds therapeutic potential for autologous implants.

Purpose of the Study:

  • To develop a lentiviral RNAi strategy to down-regulate ADK in human mesenchymal stem cells (hMSCs).
  • To assess the therapeutic potential of engineered hMSCs for adenosine-dependent neuroprotection.

Main Methods:

  • Construction of lentiviral vectors co-expressing miRNA targeting ADK and EmGFP reporter.
  • Transduction of hMSCs with lentiviral vectors.
  • Assessment of ADK down-regulation, transduction efficiency, and EmGFP expression over passages.
  • Evaluation of engineered hMSC graft survival and neuroprotective effects in a mouse model of seizure-induced cell loss.

Main Results:

  • Achieved up to 80% down-regulation of ADK and 98% transduction efficiency in hMSCs.
  • Transduced hMSCs maintained EmGFP expression through multiple passages.
  • Engineered hMSC grafts survived in the mouse brain and demonstrated adenosine-dependent neuroprotection.

Conclusions:

  • Lentiviral RNAi-mediated ADK down-regulation is effective in engineering therapeutic adenosine-releasing hMSCs.
  • Engineered hMSCs show promise for autologous cell-based therapies, particularly in neuroprotection.
  • This approach offers a viable strategy for developing patient-specific implants for clinical applications.